# Wearable Sensor and Digital Technologies for Quantitative Assessment and Remote Monitoring of Symptoms in Myasthenia Gravis

> **NIH NIH R44** · BIOSENSICS, LLC · 2022 · $500,000

## Abstract

PROJECT SUMMARY
Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disease characterized by fluctuating muscle
weakness and symptoms that interfere with activities of daily living and negatively impacts quality of life. MG
symptoms are currently assessed in person through a careful history and physical exam by a neuromuscular
disease expert. Such in-clinic assessments are time-consuming, subjective, only provide a snapshot of a
patient's disease and do not adequately reflect the spectrum of fluctuating weakness and symptoms.
In 2019, NIH funded a rare disease clinical research consortium called MGNet. The consortium is focused on
improved characterization of clinical phenotypes, discovery of biomarkers, and advancing clinical trial readiness
for MG, which would enhance the development of more effective and personalized treatments. In this Fast Track
SBIR project, BioSensics will collaborate with Massachusetts General Hospital - one of the key Consortium sites
for MGNet that provides care to approximately 200 MG patients - to develop and validate a wearable sensor
solution (MGWear) for continuous remote monitoring of motor symptoms and function in MG patients and also
a secure mobile application (MG app) for automatic assessment of speech and facial characteristics (i.e.
dysarthria and ptosis), which are the most common symptoms of MG. The mobile application will also enable
the transfer of data from the wearable device to BioSensics HIPAA-compliant backend cloud called BioDigit
Cloud that can be accessed via a secure website.
The project will complement outcome and biomarker research by MGNet and represent significant public health
need and market opportunity for BioSensics. A key application and market for the proposed solution technology
is pharmaceutical clinical trials. Wearable sensors and digital technologies like the technology proposed here
will allow drug developers to test and iterate faster, providing a valuable new method for evaluating efficacy.
BioSensics is a leader in providing wearable sensor and digital technologies for clinical trials. This project will
significantly broaden BioSensics offerings and capabilities by providing mobile health (mHealth) technologies for
remote monitoring of motor symptoms, speech and ptosis in MG and other neurological diseases. Clinically, the
proposed solution can be used to predict an individual's response to immunosuppressive drugs and to improve
mediation titration. Such solutions can enable detecting subtle changes in movement-based and digital
biomarkers and provide insight into the phase of clinical disease onset. Additionally, the growing use of
telemedicine to expand access and potentially reduce costs of high-quality care will require remote assessment
strategies. 20% of states in the US (10 out of 50 states) have no specialized care for MG. Travel time, distance
and cost may limit patients' access to expert care, even in states with identified MG specialists. The proposed
remot...

## Key facts

- **NIH application ID:** 10470564
- **Project number:** 1R44NS122672-01A1
- **Recipient organization:** BIOSENSICS, LLC
- **Principal Investigator:** Amanda Guidon
- **Activity code:** R44 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $500,000
- **Award type:** 1
- **Project period:** 2022-09-15 → 2024-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10470564

## Citation

> US National Institutes of Health, RePORTER application 10470564, Wearable Sensor and Digital Technologies for Quantitative Assessment and Remote Monitoring of Symptoms in Myasthenia Gravis (1R44NS122672-01A1). Retrieved via AI Analytics 2026-09-16 from https://api.ai-analytics.org/grant/nih/10470564. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*